Week of April 11, 2022 | Vol. 11, Issue 15 |
|
|
In This Issue
Upcoming Events
Industry M&A Activity
Recent Transactions
Trading Comps
Market Reports
M&A Pipeline
Featured Headlines
Tanner Updates
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. Click on the chart to download complete transaction tables broken out by industry sub sectors. For additional information, see the Industry M&A Activity section below.
|
|
Events Hosted or Attended by Bourne Partners
|
|
|
|
May 17-19, 2022 - Philadelphia, PA
|
|
|
|
May 24-26, 2022 - New York City, NY
|
|
|
|
April 23-26, 2022 - Palm Beach, FL
|
|
|
|
June 13-16, 2022 - San Diego, CA
|
|
|
|
August 27-29, 2022 - Boston, MA
|
|
|
|
October 2022 - Charlotte, NC
|
|
INDUSTRY M&A ACTIVITY
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
|
|
RECENT TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
|
|
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions. |
|
|
|
Pharma & Biotech
10 transactions totaling $931 million
Supplies, Equipment & Services
20 transactions totaling $6,616 million
Healthcare IT & Managed Care
6 transactions totaling $36 million
Healthcare Facilities & Distributors
12 transactions totaling $586 million
|
|
|
|
Pharma & Biotech
50 transactions totaling $609 million
Supplies, Equipment & Services
27 transactions totaling $296 million
Healthcare IT & Managed Care
34 transactions totaling $443 million
Healthcare Facilities & Distributors
4 transactions totaling $109 million
|
|
|
|
Pharma & Biotech
17 transactions totaling $829 million
Supplies, Equipment & Services
1 transaction totaling $3 million
Healthcare IT & Managed Care
2 transactions totaling $23 million
Healthcare Facilities & Distributors
1 transaction
|
|
TRADING COMPS
A Breakdown of Relevant Trading Multiples
|
|
|
|
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
MARKET REPORTS
Insight Into Healthcare Related Industries
|
|
M&A PIPELINE
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Gateway
Sell-side | Pharma | Generic pharmaceuticals
Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
|
|
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
|
|
FEATURED HEADLINES
A Sampling of Industry Headlines From Last Week
|
|
It was a presentation at the American Society of Hematology (ASH) conference that swayed Jazz Pharmaceuticals to put up $15 million upfront to join Werewolf Therapeutics on the prowl.
The backloaded biobucks deal will see the two companies work on a candidate that goes after difficult and unresponsive tumors. The relatively small upfront payment to Werewolf will easily be eclipsed by $1.26 billion in potential development and regulatory milestone fees if all goes well. Through the deal, Jazz will gain exclusive global development and commercialization rights to WTX-613, a conditionally activated interferon alpha molecule.
WTX-613 is in preclinical development at the moment, and Jazz aims to apply for human study with the FDA in 2023. The therapy is meant to avoid the severe toxicities that occur with certain immunotherapies, which help harness the immune system to fight cancer. WTX-613 is being developed to work alone or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors.
|
|
April 4, 2022 - Fierce Healthcare
|
With billions of dollars pouring into healthcare every year and countless new technologies emerging, healthcare businesses in the U.S. are thriving. |
|
April 5, 2022 - Fierce Biotech
|
In a deal nearly two years in the making, Bioventus has opted to acquire fellow orthopedic devicemaker CartiHeal—less than a week after CartiHeal announced its flagship cartilage repair implant Agili-C had been approved by the FDA. |
|
April 5, 2022- Fierce Biotech
|
Regenerative medicine couldn't stop making news in 2021. The year was marked by Intellia's first results in humans for gene editing, massive Big Pharma partnerships and record investment of $22.7 billion. |
|
April 6, 2022- Fierce Biotech
|
To help boost its drug discovery and development work in cardiovascular disease, Valo Health is acquiring TARA Biosystems, makers of a 3D heart tissue modeling platform. |
|
TannerMAP works across the broad spectrum of pharma services, creating opportunities that benefit manufacturers and patients alike. Learn more about the division from industry veterans and Tanner EVPs, Rob Keel and John Lagus. |
|
When demand for PPE and testing kits surged to unparalleled levels in March 2020 during the first wave of Covid-19, Tanner had to do something to help. Learn more about the development of TannerGMS (global medical supplies) and the future of medical supplies and diagnostics here. |
|
The Tanner team will be attending several networking events in the coming weeks. Let’s connect to discuss how our organizations can improve patient lives, together.
|
|
|
|
|
|
|
